52477-97-1

Usage

InChI:InChI=1/C16H26O3/c1-2-3-13-19-16(18)12-7-5-4-6-9-14-10-8-11-15(14)17/h10H,2-9,11-13H2,1H3

Upstream product

• 936-52-7 1-(N-morpholino)cyclopent-1-ene 
• 35923-65-0 6-formyl hexanoic acid 
• 71-36-3 butan-1-ol 
• 78426-89-8 Methyl 7-(2-oxocyclopentylidene)-heptanoate 
• 79070-37-4 2-(6-butoxycarbonylhexyl)-cyclopentanone 
• 818-38-2 Diethyl glutarate 
• 6838-66-0 1,2-bis((trimethylsilyl)oxy)cyclopent-1-ene 
• 5239-43-0 7-(5-oxo-1-cyclopenten-1-yl)heptanoic acid 
• 3296-46-6 4-(2-oxocyclopentyl)butanoic acid 
• 52477-96-0 1-methoximino-2-(6-carboxyhexyl)-2-cyclopentene 
• 52477-95-9 1-methoximino-2-(6,6-dicarboxyhexyl)-2-cyclopentene 
• 42301-65-5 4-bromo-2-(6-carboxyhexyl)cyclopent-2-en-1-one 
• 67728-51-2 7-(1-Hydroxy-2-oxo-cyclopentyl)-heptanoic acid methyl ester 
• 35376-00-2 methyl 7-oxoheptanoate 

Downstream Products

• 21269-27-2 11-Desoxyprostaglandin E₁ 
• 21269-27-2 7-[(R)-2-((E)-(R)-3-Hydroxy-oct-1-enyl)-5-oxo-cyclopentyl]-heptanoic acid 
• 78200-04-1 butyl 7β-(1-benzamido-3-oxo-trans-1-octenyl)-1,4-dioxaspiro<4.4>nonane-6α-heptanoate 
• 78200-05-2 7-[(6R,7S)-7-((Z)-1-Benzoylamino-3-hydroxy-oct-1-enyl)-1,4-dioxa-spiro[4.4]non-6-yl]-heptanoic acid butyl ester 

Relevant academic research and scientific papers

PROSTANOIDS. XII. SYNTHESIS OF THE KEY SYNTHONS AND SOME α-HOMOANALOGS OF 11-DEOXYPROSTAGLANDIN E1

The cuprate synthesis of the di-, tri,- tetra,- and pentahomoanalogs of 11-deoxyprostaglandin E1 was realized from the corresponding α-homo-2-(butoxycarbonylalkenyl)-2-cyclopenten-1-ones.The latter were obtained by the condensation of 1-morpholinocyclopentene with α,ω-aldehydo esters, prepared by ozonolytic cleavage of cyclic olefins, E,E,E-cyclododecatriene, and undecylenic acid.

TOTAL SYNTHESIS OF PROSTAGLANDINS. IV*. SYNTHESIS OF 2-(6-ALKOXYCARBONYLHEXYL)CYCLOPENT-2-EN-1-ONES

A preparative method was developed for the synthesis of 2-(6-alkoxycarbonylhexyl)cyclopent-2-en-1-ones by the bromination of the respective 2-(6-alkoxycarbonylhexyl)cyclopentan-1-ones with N-bromosuccinimide, followed by dehydrobromination of the bromine-substituted compounds and isomerization of the 2-(6-alkoxycarbonylhexylidene)cyclopentan-1-ones formed as side products.

Novel 11-alkoxy-9-keto (or hydroxy)-prostenoic acid derivatives and method for preparing same

This disclosure describes certain 11-alkoxy-9-keto- (or hydroxy)-prostenoic acid derivatives useful as anti-microbial agents, hypotensive agents, anti-ulcer agents, or as intermediates.

Novel prostaglandins

This disclosure describes novel 15-hydroxy prostanoic acid derivatives having anti-ulcer, bronchodilator, and hypotensive activity.

Cycloalkyl and cycloalkenyl prostaglandin congeners

This disclosure describes novel 15-hydroxy prostanoic acids and derivatives thereof useful as bronchodilators, hypotensive agents and gastric acid secretion inhibitors (anti-ulcer).

Hydro substituted prostanoic acids and esters

This disclosure describes certain 11-hydroxy and 11-deoxy-9-keto (or hydroxy)prostanoic acid derivatives useful as bronchodilators, anti-ulcer agents, or as intermediates.

Novel 11-hydroxy-9-keto-5,6-cis-13,14-cis-prostadienoic acid derivatives

This disclosure describes certain 11-hydroxy and 11-deoxy-9-keto(or hydroxy)-prostanoic acid derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents, or as intermediates.

Derivatives of 9-hydroxy-13-trans-prostenoic acid

This disclosure describes certain 15-deoxy prostanoic acid derivatives having a hydroxy group further along in the beta-chain, useful as bronchodilators, hypotensive agents, anti-ulcer agents, or as intermediates.

3-Alkyl-2-(6-carboxyhexyl)cyclopentanones and esters and salts thereof

This disclosure describes compounds of the class of substituted 9-oxoprostanoic acids and the esters and cationic salts thereof, useful as antimicrobial agents, hypotensive agents, anti-ulcer agents, or as intermediates, and novel processes for preparing the same.